Jasper scraps pivotal plans but adds a new indication as more biotechs revise pipelines

A suite of biopharmas disclosed cuts to their pipelines this week as the industry gets a sweeping update of drugs in the works as part of the annual JP Morgan Healthcare Conference.

Jasper Therapeutics, Acticor Biotech, NGM Bio and Annexon were among those to slash parts of their development plans.


Click to view original post